share_log

6-K: Articles of Association of Novo Nordisk A/S

SEC announcement ·  Apr 25 18:10
Summary by Futu AI
Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on April 24, 2024. The report, which is a requirement for foreign companies listed on U.S. stock exchanges, provides updates and information that the company deems significant. The submission of the Form 6-K indicates Novo Nordisk A/S's compliance with the SEC's rules, specifically Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document was officially signed by an authorized representative of Novo Nordisk A/S on the date of filing. The company's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.
Novo Nordisk A/S, a foreign private issuer, has submitted a Form 6-K report to the United States Securities and Exchange Commission (SEC) on April 24, 2024. The report, which is a requirement for foreign companies listed on U.S. stock exchanges, provides updates and information that the company deems significant. The submission of the Form 6-K indicates Novo Nordisk A/S's compliance with the SEC's rules, specifically Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934. The document was officially signed by an authorized representative of Novo Nordisk A/S on the date of filing. The company's principal executive offices are located at Novo Allé 1, DK-2880, Bagsvaerd, Denmark.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.